Palvella Therapeutics PVLA Royalty Agreement Liability
Royalty Agreement Liability at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept pvla:RoyaltyAgreementLiability.
The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's royalty agreement liability.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's royalty agreement liability?
- Palvella Therapeutics (PVLA) reported royalty agreement liability of $19.8M in Q1 2026.
- How has Palvella Therapeutics's royalty agreement liability changed year-over-year?
- Palvella Therapeutics's royalty agreement liability increased by 50.5% year-over-year, from $13.16M to $19.8M.
- What is the long-term trend for Palvella Therapeutics's royalty agreement liability?
- Over 2 years (2023 to 2025), Palvella Therapeutics's royalty agreement liability has grown at a 48.5% compound annual growth rate (CAGR), from $8.05M to $17.76M.
- What does royalty agreement liability mean?
- This represents the present value of future payment obligations owed to third parties based on licensing agreements or intellectual property rights associated with the company's product pipeline. It reflects the long-term financial burden of external technology acquisition or development partnerships. Investors use this to assess the impact of future revenue sharing on the company's long-term profitability and capital structure.